Navigation Links
MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020

DALLAS, November 17, 2011 /PRNewswire/ --

The report "Prostate Cancer Therapeutics Market (2010-2020) (Opportunity Analysis, Pipeline Assessment and Global Market Forecast) []", as the name suggests, analyzes and studies the major market drivers, restraints, and opportunities in North America (U.S. & Canada), Europe (Germany, France, U.K., Italy, and Spain) and emerging markets (Brazil, India, China, Russia, Turkey, and South Korea).

Browse market data tables and in-depth TOC on Prostate Cancer Therapeutics Market (2010-2020) (Opportunity Analysis, Pipeline Assessment and Global Market Forecast).
Early buyers will receive 10% customization on reports.

The prostate is an exocrine gland found in men, located in the groin area just below the bladder and in front of the rectum. In prostate cancer, cells within the gland mutate into cancer cells. Further, these affected cells start killing the other healthy gland cells, and can spread to the other body parts. Prostate cancer is the second leading cause of new cancer cases in men worldwide and the sixth leading cause of cancerous death in men. Globally, about 899,000 men were diagnosed with prostate cancer in 2008 and it is estimated that this number will get doubled (1.7 million) by 2030.

Global prostate cancer therapeutics market [ ] was valued at $2,713 million in 2010 and it is expected to reach $6,457 million, by 2020. It is estimated that the market will grow at a CAGR of 11.4% and 6.8% from 2010 to 2015 and 2015 to 2020 respectively. By therapy, hormonal therapy is dominating the global prostate cancer drugs market with 66% market share in 2010 and expected to account for 53% market share in 2020. However, by 2020, immunotherapy and targeted therapy will significantly gain market share due to advantages such as increase in the overall survival and progression free survival with benign side effects profile.

In 2010, Europe dominated the global prostate cancer drug market by accounting to 43% market share; followed by Europe is North America with the share of 42%.

The major players in the market as of 2010 include AstraZeneca PLC (U.K.), Sanofi-Aventis (France), Ipsen (France), Tolmar Inc (U.S.), Abbott (U.S.), Astellas Pharma Inc (Japan), Indevus Pharmaceuticals Inc (U.S.), Dendreon Corporation (U.S.), and Ferring Pharmaceuticals (Switzerland).

Other Reports by MarketsandMarkets

Upcoming Market Research by MarketsandMarkets

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical, pharmaceuticals [ ], semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website

Mr. Rohan
7557 Rambler Road,
Suite 727, Dallas, TX 75231
Tel: +1-888-6006-441
MarketsandMarkets Blog @

SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014
2. MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014
3. Marketsandmarkets: Global Minimally Invasive/ Non Invasive Market Worth $24.4 Billion by 2014
4. MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014
5. MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014
6. MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014
7. MarketsandMarkets: Global Biochip (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Market to Reach $5.6 Billion by 2015
8. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
9. Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response
10. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
11. Forward step in forecasting global warming
Post Your Comments:
(Date:10/11/2017)... Tampa Bay, Florida (PRWEB) , ... October 11, ... ... Food and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its ... antibody (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second ... a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, ... from US2020. , US2020’s mission is to change the trajectory of STEM education ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
Breaking Biology News(10 mins):